Business
Grant of European Patent
Grant of European Patent.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \n PROTEOME SCIENCES plc \n\n PRESS RELEASE \n\n Grant of European Patent \n\n On Isobaric Tandem Mass Tags® (TMT®) \n\n15 May 2007. Proteome Sciences plc (\"Proteome Sciences\") is pleased to announce\nthat the European Patent Office has today posted that the Grant for its\nEuropean patent application in isobaric mass labelling for its tandem mass tags\n(TMT®) entitled \"Selective Acquisition of Mass Markers\" Serial No. 01911912.2\n(TMT1) will be published on 13th June, 2007. This follows grants of the\ncorresponding cases in Australia, New Zealand and Canada. The European Patent\ncontains broad claims to isobaric mass tags and methods of their use as\nchemical reagents to label proteins.\n\nThe Grant of TMT1 is a major milestone for Proteome Sciences because it will\nenable the company to approach entities using isobaric mass labels in Europe\nand to alert them that they can obtain licences from Proteome Sciences for the\nmanufacture or use of any type of isobaric mass tags in their research\nprogrammes. These licences will allow revenue to be generated from any\napplications in the field of isobaric mass tagging.\n\nCommenting on the Grant of TMT1, Christopher Pearce, Chief Executive of\nProteome Sciences said:\n\n\"The Grant of TMT1 in Europe puts Proteome Sciences in an outstanding position\nto generate substantial revenues from a combination of licence payments,\nback-licence payments, product sales and royalties. The market for isobaric\ntandem mass tags continues to grow disproportionately fast and earlier\nestimates over the patent lives appear to have considerably underestimated the\nscale and importance of quantitative mass spectrometry.\n\nThe TMT1 and TMT2 patent applications in the USA are in the final stages of\nprocessing and we anticipate that these too will be concluded shortly.\n\nNew applications for TMT® have and are being developed that will add to this\ngrowth. Today we are presenting one such new application at the Biomarker World\nCongress in Philadelphia, USA where we will demonstrate TMT® labelled plasma\nreference for MS/MS quantification of individual samples using mass\nspectrometry.\n\nThis heralds the development of a new universal reference material based on TMT\n® validated with human samples showing dramatic improvement in the\nreproducibility and comparability of proteomics studies w...